- Home
- ATYR vs OPFI Comparison
ATYR vs OPFI Comparison
Compare ATYR & OPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- OPFI
- Stock Information
- Founded
- ATYR 2005
- OPFI 2009
- Country
- ATYR United States
- OPFI United States
- Employees
- ATYR N/A
- OPFI N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- OPFI Finance: Consumer Services
- Sector
- ATYR Health Care
- OPFI Finance
- Exchange
- ATYR Nasdaq
- OPFI Nasdaq
- Market Cap
- ATYR 306.2M
- OPFI 363.8M
- IPO Year
- ATYR 2015
- OPFI N/A
- Fundamental
- Price
- ATYR $5.22
- OPFI $12.86
- Analyst Decision
- ATYR Strong Buy
- OPFI Buy
- Analyst Count
- ATYR 6
- OPFI 2
- Target Price
- ATYR $20.20
- OPFI $11.75
- AVG Volume (30 Days)
- ATYR 2.5M
- OPFI 1.4M
- Earning Date
- ATYR 08-12-2025
- OPFI 08-06-2025
- Dividend Yield
- ATYR N/A
- OPFI 1.95%
- EPS Growth
- ATYR N/A
- OPFI N/A
- EPS
- ATYR N/A
- OPFI N/A
- Revenue
- ATYR N/A
- OPFI $305,566,000.00
- Revenue This Year
- ATYR $960.85
- OPFI $112.80
- Revenue Next Year
- ATYR $1,283.47
- OPFI $9.34
- P/E Ratio
- ATYR N/A
- OPFI N/A
- Revenue Growth
- ATYR N/A
- OPFI 31.46
- 52 Week Low
- ATYR $1.42
- OPFI $3.09
- 52 Week High
- ATYR $5.98
- OPFI $17.73
- Technical
- Relative Strength Index (RSI)
- ATYR 62.87
- OPFI 54.44
- Support Level
- ATYR $5.02
- OPFI $11.60
- Resistance Level
- ATYR $5.98
- OPFI $12.69
- Average True Range (ATR)
- ATYR 0.45
- OPFI 0.69
- MACD
- ATYR -0.04
- OPFI -0.22
- Stochastic Oscillator
- ATYR 52.94
- OPFI 44.21
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.